Unlock Strategic Intelligence with Fundz
Access exclusive insights on funding rounds, strategic shifts with FundzWatch™, Family Offices, and more — faster than your competitors.
Degron Therapeutics Raises $22M Series A Financing To Accelerate Growth And Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
Degron Therapeutics Raises $22M Series A Financing To Accelerate Growth And Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform
06/09/22, 5:00 AM
Money raised
$22 million
Round Type
series a
Degron Therapeutics ("Degron"), a biotechnology company developing a new class of small-molecule medicines that target previously undruggable targets, today announced it has closed a $22 million Series A financing round led by Med-Fine Capital. Additional investors participating in the financing round included Dyee Capital, Baidu Venture, and NeuX Capital, along with Degron's seed investors, CO-WIN Ventures and Yuanbio Venture Capital.
🔒 Strategic shifts and deeper insights are available for this company. Unlock full access to view hidden updates, executive moves, and more.
Company Info
Additional Info
Degron Therapeutics is a biotechnology company advancing human health by developing novel medicines using its robust molecular glue-based targeted protein degradation drug discovery platform. The company's unique GlueXplorer® platform has created a rapidly expanding IP-protected compound library and screening system to develop a new class of small-molecule medicines that target previously undruggable disease targets. The company's pipeline includes a growing number of preclinical compounds for oncology, inflammation, metabolic disease, and rare diseases. For more information, please visit www.degrontx.com.
SOURCE Degron Therapeutics
Track Every New Funding Round — Before Anyone Else
This is just a small preview. Unlock access to thousands more filtered results — updated in real-time by stage, region, investor & more.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.